ImmunityBio, Inc.

ImmunityBio, Inc.

IBRXNYSE / NASDAQHealthcareSmall cap

$6.02-$0.55 (-8.4%)

Last close · Data as of Nov 20, 2026

Market cap
$7.6B
P/E
-21.7x
EV / EBITDA
-36.1x
Revenue
$113.3M
Net margin
-310.2%
ROCE
-58.2%

+198.0% over the last year

ImmunityBio, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-31.4%
3M
-23.2%
6M
-25.2%
1Y
+198.0%
5Y
Hidden
  • This period includes a one-day price step on 11 May 2023 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.55 (-8.4%) from $6.57 to $6.02 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IBRX, bought on each weekday since 2021.

News & filings

What ImmunityBio filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Read moreShow less

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Sector
Healthcare
Shares outstanding
1.01B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$7.6B
P/E
-21.7x
P/B
-15.3x
EV / EBITDA
-36.1x
EV / Sales
71.2x
P/S
67.4x
52-week high
$11.55
52-week low
$1.98

Profitability

Operating margin
-226.0%
Net margin
-310.2%
EBITDA margin
-197.3%
ROE
70.2%
ROCE
-58.2%
ROA
-70.0%
Asset turnover
0.23

Growth

Revenue
$113.3M
Revenue growth, 1Y
668.3%
Revenue CAGR, 3Y
678.6%
Net profit growth, 1Y
-15.0%
Free cash flow
-$309.2M

Solvency

Current ratio
5.10
Debt / Equity
-1.04
Debt / Assets
1.03
CFO / Net profit
0.87
Cash / Market cap
1.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$113.3M
Cost of revenue$750.0k
Gross profit$112.5M
Operating expenses$368.6M
Research and development$218.6M
Selling, general and administrative$150.0M
Operating income-$256.0M
Interest and other-$95.6M
Pretax income-$351.6M
Tax and other-$210.0k
Net income-$351.4M

Revenue and net profit

Revenue grew 668.3% in FY2025; net profit is the dashed line.

ImmunityBio, Inc. revenue and net profit by fiscal year
ImmunityBio, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$240.0k-$416.6M
FY2023$622.0k-$583.2M
FY2024$14.7M-$413.6M
FY2025$113.3M-$351.4M

Cash flows

FY2025: -$304.9M from operations, -$309.2M free after investment (dashed).

ImmunityBio, Inc. operating and free cash flow by fiscal year
ImmunityBio, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$337.5M-$436.9M
FY2023-$366.8M-$397.3M
FY2024-$391.2M-$398.1M
FY2025-$304.9M-$309.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$113.3M+668.3%1Y
EBITDA
-$223.6M
Net profit
-$351.4M
Cash from operations
-$304.9M
Free cash flow
-$309.2M
Revenue CAGR, 3Y
678.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$113.3M-$223.6M-$351.4M-$309.2M70.2%+668.3%-15.0%

Monthly returns

Month-by-month returns of IBRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$501.9M
Liabilities$1.0B
Equity-$499.6M
Paid-in capital$3.2B
Retained earnings-$3.7B
Minority interest$900.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IBRX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. ImmunityBio, Inc. (this company)71.2x

Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc., Praxis Precision Medicines, Inc., Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ImmunityBio, Inc.IBRXthis company$7.6B-21.7x-15.3x70.2%-36.1x
Nuvalent, Inc.NUVL$7.4B-17.5x5.9x-34.1%—
Praxis Precision Medicines, Inc.PRAX$7.4B-24.3x8.4x-34.5%-21.5x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Peer median—-17.5x7.4x-31.3%-21.5x

Year-to-date ROI

IBRX since 1 January, against earlier years.

Historical volatility

IBRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

ImmunityBio, Inc. operating margin by fiscal year
ImmunityBio, Inc. operating margin by fiscal year
DateOperating margin
FY2022-146091.7%
FY2023-58283.9%
FY2024-2335.0%
FY2025-226.0%
LineFY2025
Cost of revenueCost Of Revenue$750.0k
Gross profitGross Profit$112.5M
Operating expensesOperating Expense$368.6M
Research and developmentResearch And Development$218.6M
Selling, general and administrativeSelling General And Administration$150.0M
Total expensesTotal Expenses$369.3M
Pretax incomePretax Income-$351.6M

Learn while you research

Academy chapters picked for ImmunityBio, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing668% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →